# Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

> **NCT04059562** · PHASE2 · COMPLETED · sponsor: **Heinrich-Heine University, Duesseldorf** · enrollment: 28 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Combination of Lonsurf® and Irinotecan

## Key facts

- **NCT ID:** NCT04059562
- **Lead sponsor:** Heinrich-Heine University, Duesseldorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-28
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-01-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059562, "Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04059562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*